- This event has passed.
Real-World Evidence (RWE) 2020
April 1 - April 2£300
Real-World Evidence 2020
Do you work in the healthcare industry, and need to learn more about how regulatory agencies and HTAs will work with real-word evidence (RWE) for rare diseases? Are you a payer trying to understand the implications of high-cost, innovative treatments? Are you a researcher looking to apply RWE in your work? A patient/patient advocate keen to learn more about the potential real-world data offers to rare disease patients? Or are you a consultant, research organisation or service provider looking to connect with RWE and HEOR experts in industry and academia?
RWE – derived from real-world patient data that are routinely collected from a variety of sources (electronic health records, patient surveys, claims databases, digital devices, and many more) – has the potential to completely alter how decisions are made to regulate, grant access to and pay for healthcare. And nowhere is the potential greater than in the research, diagnosis and treatment of rare diseases, where randomised controlled trials are highly challenging, if not impossible, to conduct, and innovative, high-cost and potentially curative therapies have the potential to turn the standard regulatory, access and reimbursement paradigms upside down.
In response to the need to convene all healthcare stakeholders – pharma, biotech & medical device companies, HTAs and regulators, payers, academics, patient advocacy groups and service providers – we have launched Real-World Evidence 2020: Rare Diseases and Innovative Therapies, in partnership with the Journal of Comparative Effectiveness Research and The Evidence Base®. Over two days, we’ll convene all members of the community who, together, can make the use of RWE in rare diseases and innovative therapies a reality.
As well as providing a platform for the presentation and discussion of ideas, offering the opportunity to connect with other stakeholders is core to the mission of Real-World Evidence 2020: Rare Diseases and Innovative Therapies. Communication is key to progressing this field, so over the two days there will be plenty of opportunities to network, meet new contacts and – of course – enjoy a drink at the evening reception!
The ethos of the event is to facilitate meaningful conversation and then, crucially, support the translation of discussion into action. In order to further drive future conversation and tangible outcomes beyond the meeting, the Journal of Comparative Effectiveness Research will be publishing a post-event White Paper, summarising the important conversations that take place, and setting the agenda for further action and themes for future meetings. We hope that the White Paper will disseminate the conversations beyond the meeting attendees to the wider community, and form the basis for even broader conversations on using RWE to support the improved management of rare diseases and use of innovative therapies.
Who will be there?
- Pharma, biotech & medical device companies
- Regulators and HTAs
- Academics and researchers in RWE, big data and HEOR
- Patient advocacy groups
- Market access specialists
- Medical communications agencies
- HEOR service providers from across the UK and Europe
What will the event look like?
Our mission is to convene a community of collaboration and best practice around the practical application of RWE in rare diseases and innovative therapies, and we have created an exciting conference format, with two zones:
- The Listen & Learn Zone comprises presentations and panels, with ample time for questions and discussion, enabling participants to learn about the latest developments.
- The Conversation & Collaboration Zone creates a space for roundtables and interactive conversations, creating an environment to share, build relationships and collaborate on future projects. The Conversation & Collaboration Zone also showcases authors from a range of Future Science Group publications, including the Journal of Comparative Effectiveness Research.
What will be discussed?
- Understanding how RWE can impact on rare diseases
- Coordination and collaboration across Europe for rare disease research
- Understanding the regulatory framework for RWE
- The development of RWE to support drug coverage and formulary decisions
- Value assessment in rare diseases and innovative therapies
- Using RWE to inform clinical trial design in rare diseases
- Achieving transparency in the generation and use of RWE
- Big healthcare data and genomics
- Rare disease registries
- Using mobile devices to gather patient health data
For more information and tickets
|Earlybird pricing (ends 7 February 2020)||Standard pricing (ends 1 April 2020)|
|Academic/public sector registration||£300||£400|